我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去）

Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
+ Author Affiliations
& Q3 q2 D" U% \) h6 v
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
6 i( M0 x4 X2 {, k! e9 n2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
" l: J+ W7 E1 J5 ]3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
& t+ }& B# [7 }9 ~6 j  \6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
1 G+ _" K& u) [2 j) F' l7Kinki University School of Medicine, Osaka 589-8511, Japan
% ?' V: O, v/ d# p  Q8Izumi Municipal Hospital, Osaka 594-0071, Japan
# ~: D, ~; h2 j# }% W- l3 {! v9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
, y& w7 V- |" ^1 S& PCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
4 Q7 O; J$ `; B9 E2 v" bAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
& X7 t& m) y5 d: g: i$ n$ y
/ l3 K' m6 V, ?/ k

S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type

Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato

8 v+ \$ p# I/ G1 AAffiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  

) ?0 a  @) U) i5 v. T7 pPublished online on: Thursday, December 1, 2011
" O; S* ~5 @; @3 t; G
Doi: 10.3892/ol.2011.507

Pages: 405-410
2 r9 B/ d& C; o9 P# K
, [+ S. z& Y% X  ^+ cAbstract:
% H0 V+ N: D3 I/ f* L6 y& g/ LS-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.
! B4 r( f" }6 w

Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3
- `9 R% w! ]! Q% _0 B$ e+ Author Affiliations
3 j8 {9 S  }$ \4 k" h8 ?1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu
" H1 n1 k3 \: ^- X2Department of Thoracic Surgery, Kyoto University, Kyoto
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan
: ]/ @. ?+ t: `& U7 F: g. `&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp
Received September 3, 2010.
8 K! b: i' L1 F+ @2 dRevision received November 11, 2010.
  J# z) V/ Q/ B* P4 F5 R, n- sAccepted November 17, 2010.
Abstract
+ y/ p% |! T: @6 i7 a/ _Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
; [: K' P, G# |% a1 n) qPatients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
Conclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.
# q' Z- G, r, z( u- m

一直关注老马的帖子，前方的指明灯。祝福你爸好疗效

一直得到老马帮助，祝福老马爸爸

26日吃了12片地米（0.75mg一片），27日吃了22片地米（0.75mg 一片），28日吃了12片地米（0.75mg一片），都分二次吃。
* F+ B* i1 B" Q, Y7 h今天为止没有任何反应，每天吃VC,VB2，还有漱口水，就怕口腔溃疡。

副作用如何，单药反应很小吧？

LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
9 B& [. `$ u) s3 M/ uhttp://clinicaltrials.gov/ct2/show/NCT01523587

5 j7 M7 X/ T9 e4 C2 U7 o' y# m( k6 uBIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
/ [7 _0 w& O+ {  Phttp://clinicaltrials.gov/ct2/show/NCT01156545

. {1 P2 M+ G2 |5 k$ I, r) B从4月24日开始到4月28日，打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
6 J- U0 z) x( U* i7 q7 b4 Z# V至今为止，未出现化疗副作用。

老马 发表于 2012-4-29 20:53

: M# p+ G$ U, @                               
登录/注册后可看大图

& r0 o( w, U% c; t从4月24日开始到4月28日，打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
' @: U0 ?  i7 U/ F: K6 X至今为止，未出 ...

0 U  Y5 E! n; L. x2 q没有副作用是第一追求，效果显著是第二追求。
4 J( t; u+ t" c' z' q不错。